Search

Displaying results 651 - 660 of 10000 in total
  1. Drug

    Cladribine

    go.drugbank.com/drugs/DB00242
    ApprovedInvestigational

    [A263733] In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment multiple sclerosis.[A263718] … [A350] Cladribine was first approved in the United States in 1993 [A263713] initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell

  2. Drug

    Nicotine

    go.drugbank.com/drugs/DB00184
    ApprovedInvestigational

    It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission.

  3. Indication

    MALT Lymphoma

    go.drugbank.com/conditions/DBCOND0031062
    Drugs: Chlorambucil
    Synonyms: Marginal zone lymphoma, Marginal Zone B-Cell Lymphoma
  4. Drug

    Erlotinib

    go.drugbank.com/drugs/DB00530
    ApprovedInvestigational

    Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. … Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
  5. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    [L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

    Categories: Orexin Receptor Antagonists
  6. Drug

    Mitomycin

    go.drugbank.com/drugs/DB00305
    ApprovedInvestigational

    [A193419] Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper … [L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix.

  7. Drug

    Potassium Iodide

    go.drugbank.com/drugs/DB06715
    ApprovedInvestigational

    SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyroidectomy.

    Mixtures: TL-Folate, RE Nata
  8. Drug

    CDX-1135

    go.drugbank.com/drugs/DB17607
    Investigational

    CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed by Avant Immunotherapeutics (now Celldex).

  9. Drug

    Pilocarpine

    go.drugbank.com/drugs/DB01085
    ApprovedInvestigational

    [A262036] Pilocarpine is used to treat dry mouth and various ophthalmic conditions, including elevated intraocular pressure and glaucoma. The usage of glaucoma by pilocarpine dates back to 1875. … A naturally occurring alkaloid derived from the _Pilocarpus_ plants, pilocarpine is a muscarinic acetylcholine agonist.

    Mixtures: E-pilo-2 Oph Soln, E-pilo-6 Oph SolnCategories: Cholinergic Receptor Agonist
  10. Drug

    Bemotrizinol

    go.drugbank.com/drugs/DB11206
    Approved

    Compared to older broad-spectrum chemical agents, bemotrizinol is more more fat soluble (oil soluble in cosmetic oils) to aid in efficacy and broad-spectrum activity [A19212]. … It is claimed to be photostable, which increases its onset of action and its efficiency in providing protection against UV-rays upon topical application [A19212, A32909].

    Mixtures: The History of Whoo Jin Hae Yoon Sun, The History Of Whoo Gong Jin Hyang Hae Yoon Sun